Spark Therapeutics Announces Sponsorship of Believe Limited’s First-Ever Science Fair for the Hemophilia Community at 2019 ...
April 17 2019 - 7:30AM
Spark Therapeutics (NASDAQ: ONCE), a fully integrated,
commercial gene therapy company dedicated to challenging the
inevitability of genetic disease, announced today that it will
serve as the inaugural sponsor of Believe Limited’s first-ever
science fair, which will be hosted at the National Hemophilia
Foundation’s 71st Bleeding Disorders Conference, Oct. 3 – 5, 2019,
in Anaheim, CA. The Science Fair™ will educate children and adults
with hemophilia as well as other attendees about the science behind
bleeding disorders in a number of engaging ways.
“Traveling around the country producing educational programs and
meeting families, we identified a growing hunger for an
understanding of the science behind our bleeding disorders from
community members of all ages,” said Patrick James Lynch, chief
executive officer, Believe Limited and a member of the bleeding
disorders community. “We wanted to bring answers – and help
families formulate smart questions – in this innovative and
accessible way.”
The exhibit’s modules will combine the interactivity of a
science center exhibit with the style of a classic school science
fair. A scientific advisory panel of key clinicians is helping
guide the educational messaging of each module, and community
members will be invited to contribute to the final program. For
more information on how you can participate in this year’s science
fair, please visit www.TheScienceFair.org.
“We believe it is important for patients and caregivers to
educate themselves about bleeding disorders. This novel
collaboration aims to spark the community’s curiosity to understand
the underlying science of their disease, so they feel empowered to
ask the right questions and make informed decisions related to
their medical care,” said Katherine A. High, M.D., president and
head of research & development, Spark Therapeutics. “We are
honored to support Believe Limited in its goal to make science
accessible to the hemophilia community.”
Following the launch at NHF BDC 2019, Believe Limited plans to
share modules of The Science Fair at future scientific and
community meetings. Additional ongoing educational content will be
available to the entire bleeding disorder community at
www.TheScienceFair.org.
About Believe Limited Believe Limited is an
award-winning boutique agency focused on creating educational,
inspirational and deeply impactful digital content, live events,
podcasts and more for rare disease communities, with a
deeply-rooted focus in hemophilia and bleeding disorders. Their
work has been honored by the National Hemophilia Foundation (NHF),
Hemophilia Federation of America (HFA) and the WEBBYs. To learn
more about their content and programming, please visit
www.BelieveLTD.com.
About Spark Therapeutics At Spark
Therapeutics, a fully integrated, commercial company committed to
discovering, developing and delivering gene therapies, we
challenge the inevitability of genetic
diseases, including blindness, hemophilia, lysosomal
storage disorders and neurodegenerative diseases. We have
successfully applied our technology in the first gene therapy
approved in both the U.S. and EU for a genetic disease, and
currently have four programs in clinical trials. At Spark, we
see the path to a world where no life is limited by genetic
disease. For more information, visit www.sparktx.com, and
follow us on Twitter and LinkedIn.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS This release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’
‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘predict,’’ ‘‘will,’’
‘‘would,’’ ‘‘could,’’ ‘‘should,’’ ‘‘continue’’ and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. We may not actually achieve the plans,
intentions or expectations disclosed in our forward-looking
statements, and you should not place undue reliance on our
forward-looking statements. Any forward-looking statements are
based on management's current expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in, or implied by, such forward-looking statements. These
risks and uncertainties include, but are not limited to, the
effects of educating patients and caregivers on bleeding disorders.
For a discussion of other risks and uncertainties, and other
important factors, any of which could cause our actual results to
differ from those contained in the forward-looking statements, see
the "Risk Factors" section, as well as discussions of potential
risks, uncertainties and other important factors, in our Annual
Report on Form 10-K, our Quarterly Reports on Form 10-Q and other
filings we make with the Securities and Exchange Commission. All
information in this press release is as of the date of the release,
and Spark Therapeutics undertakes no duty to update this
information unless required by law.
Media
Contact:Believe LimitedRob
Bradfordrob@believeltd.com Spark Therapeutics
Monique da Silvacommunications@sparktx.com (215) 282-7470 |
|
Onconetix (NASDAQ:ONCE)
Historical Stock Chart
From Feb 2025 to Mar 2025
Onconetix (NASDAQ:ONCE)
Historical Stock Chart
From Mar 2024 to Mar 2025